Related references
Note: Only part of the references are listed.MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT/IL-1β/Wnt/β-catenin signaling pathway in ovarian cancer
May Mohammed Alrashed et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2022)
Citric acid of ovarian cancer metabolite induces pyroptosis via the caspase-4/TXNIP-NLRP3-GSDMD pathway in ovarian cancer
Xiaogang Wang et al.
FASEB JOURNAL (2022)
miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway
H. Wu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway
Chaoqing Zhong et al.
FRONTIERS IN IMMUNOLOGY (2021)
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer
Sara Socorro Faria et al.
JOURNAL OF BIOMEDICAL SCIENCE (2021)
Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving
De-Ying Wang et al.
CANCER RESEARCH AND TREATMENT (2020)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway
Qiao Zheng et al.
BIOSCIENCE REPORTS (2020)
NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
Shaima'a Hamarsheh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
Junli Deng et al.
BMC CANCER (2019)
Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
Jane Antony et al.
PHYSICAL BIOLOGY (2019)
MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis
S. Li et al.
ONCOGENE (2018)
LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions
Xingyan Ju et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Diagnosis and Treatment of Ovarian Cancer
Brian Orr et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Role of the NLRP3 inflammasome in cancer
Maryam Moossavi et al.
MOLECULAR CANCER (2018)
The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
Xiaodong Feng et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Epidemiology of ovarian cancer: a review
Brett M. Reid et al.
CANCER BIOLOGY & MEDICINE (2017)
Acquired chemotherapy resistance in ovarian cancer
E. L. Christie et al.
ANNALS OF ONCOLOGY (2017)
Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells
Hong Wang et al.
EXPERIMENTAL CELL RESEARCH (2016)
Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression
Qing Wei et al.
LABORATORY INVESTIGATION (2014)
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
Sergio Marchini et al.
EUROPEAN JOURNAL OF CANCER (2013)
Beneficial and detrimental oles of NLRs in carcinogenesis
Ann M. Janowski et al.
FRONTIERS IN IMMUNOLOGY (2013)
Genetic variation and alterations of genes involved in NFκB/TNFAIP3-and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer
Jonas Ungerback et al.
CARCINOGENESIS (2012)
Epithelial-mesenchymal transition in tumor metastasis: a method to the madness
Venkateshwar G. Keshamouni et al.
FUTURE ONCOLOGY (2009)
The NLR gene family: A standard nomenclature
Jenny P. -Y. Ting et al.
IMMUNITY (2008)
Complex networks orchestrate epithelial-mesenchymal transitions
JP Thiery et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Share Paper
